Hispanic and Latino Americans represent approximately 19% of the U.S. population, nearly 63 million people, yet they participate in clinical trials at rates significantly below this proportion. This underrepresentation has real consequences for the health of millions of Americans.
The Numbers
A 2022 FDA analysis found that Hispanic patients represented only approximately 11% of clinical trial participants in FDA approval applications, significantly below their population share.
Why Representation in Research Matters
Biological differences in drug response. Genetic variations in drug-metabolizing enzymes differ in frequency across ancestral groups. Treatment efficacy and adverse effect profiles can differ meaningfully, but this can only be known if diverse populations participate in the trials.
Disease prevalence differences. Type 2 diabetes, hypertension, and certain cancers occur at different rates and with different characteristics in Hispanic populations.
Trust and community benefit. When a community’s members participate in trials, the results are more applicable to that community, and the trust built through participation has broader public health benefits.
Barriers to Hispanic Participation
- Language barriers, English-only study documents and coordinators
- Transportation and work schedule challenges
- Historical mistrust of medical institutions
- Immigration status concerns (which are unfounded, trial participation does not involve immigration authorities)
- Lack of information about what trials are and who can participate
What NuLine Does Differently
NuLine Clinical Trial Center in Oakland Park serves one of the most culturally diverse communities in Florida. Our staff includes Spanish-speaking coordinators. All study procedures are explained in the participant’s primary language. Transportation assistance is available in many studies.